Ruxolitinib Extended Release Dosage Forms
Sustained release formulations of ruxolitinib address the challenges of frequent dosing and side effects by maintaining therapeutic plasma concentrations, enhancing patient compliance and efficacy in treating JAK-related diseases.
Patent Information
- Application Number
- JP2023017676
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2013-02-26
- Filing Date
- 2023-02-08
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2033-11-14
AI Technical Summary
Ruxolitinib, a Janus kinase (JAK) inhibitor, has a short half-life and rapid oral absorption, necessitating multiple daily doses and leading to undesirable side effects such as thrombocytopenia and anemia, which complicates patient compliance and treatment efficacy.
Development of sustained release formulations of ruxolitinib or its pharmaceutically acceptable salts, designed to maintain therapeutic plasma concentrations for extended periods, reducing the frequency of dosing and minimizing side effects.
The sustained release formulations provide continuous, therapeutically effective plasma concentrations with reduced dosing frequency, minimizing side effects like thrombocytopenia and anemia while maintaining treatment efficacy for JAK-related diseases.
Smart Images

Figure 0007577146000018 
Figure 0007577146000019 
Figure 0007577146000020
Abstract
Description
[Technical field]
[0001] The present invention relates to sustained release formulations and dosage forms of ruxolitinib, or a pharma- ceutically acceptable salt thereof, that are useful in the treatment of Janus kinase-associated diseases, such as myeloproliferative disorders. [Background technology]
[0002] Ruxolitinib ((3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile) is the first FDA approved Janus kinase (JAK) inhibitor and the only drug currently approved for the treatment of myelofibrosis. Mascarenhas, J. et al., Clin Cancer Res. 2012 Jun 1;18(11):3008-14. Epub 2012 Apr 2. The compound has been shown in clinical trials to effectively reduce spleen volume and improve total symptom scores in patients with myelofibrosis. See, e.g., Verstovsek, S. et al., "A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis," N. Eng. J. Med., 2012, Mar 1:366(9):799-807, which is incorporated by reference in its entirety, reporting the results of a phase 3 clinical trial of ruxolitinib for myelofibrosis (the COMFORT-I trial). See also, Harrison, C. et al., "JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis," N. Eng. J. Med., 2012, Mar 1;366(9):787-98, which is incorporated by reference in its entirety, reporting the results of a phase 3 clinical trial of the COMFORT-II trial.
[0003] To date, all published human clinical data on ruxolitinib are related to administration of immediate release formulations. However, ruxolitinib is a BCS class I molecule with rapid oral absorption and a short half-life of about 3 hours. See Shi et al., J.Clin.Pharmacol.2012 Jun;52(6):809-18.Epub 2011 May 20 (Non-Patent Document 4). These characteristics lead to multiple daily doses for optimal treatment, resulting in a maximum / minimum plasma concentration ratio in human subjects, potentially contributing to patient compliance issues and undesirable side effects.
[0004] Ruxolitinib therapy is often associated with the adverse events of thrombocytopenia (low platelet count) and anemia (low hemoglobin). Thrombocytopenia is dose-dependent and is considered the dose-limiting toxic effect. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Mascarenhas, J. et al. Clin Cancer Res. 2012 Jun 1;18(11):3008-14. Epub 2012 Apr 2 [Non-Patent Document 2] Verstovsek, S. et al. “A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis,” N.Eng.J.Med., 2012, Mar 1:366(9):799-807 [Non-Patent Document 3] Harrison, C. et al. “JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis,” N.Eng.J.Med., 2012, Mar 1;366(9):787-98 [Non-Patent Document 4] Shi et al. J.Clin.Pharmacol.2012 Jun;52(6):809-18.Epub 2011 May 20 Summary of the Invention [Problem to be solved by the invention]
[0006] Thus, there is a need for new and improved formulations of ruxolitinib that not only reduce adverse side effects in patients, but also still obtain a therapeutic effect and further facilitate administration of the drug, such as by reducing the number of doses required to obtain a therapeutic effect. The sustained release formulations provided herein help meet these and other needs. [Means for solving the problem]
[0007] The present invention relates to a sustained release dosage form comprising at least one active ingredient which is ruxolitinib or a pharma- ceutically acceptable salt thereof, wherein ruxolitinib or a pharma- ceutically acceptable salt thereof is present in the dosage form in an amount of about 10 to about 60 mg, based on the free base.
[0008] The present invention further relates to a method of treating a disease associated with JAK activity in a patient in need thereof comprising administering to said patient a sustained release dosage form of the present invention. [Brief description of the drawings]
[0009] [Figure 1] FIG. 1 is a graph comparing plasma concentrations of ruxolitinib following administration of a single dose of either a 25 mg immediate release or a 25 mg extended release formulation in fasted healthy human subjects. [Diagram 2] 1 is a graph comparing spleen volume responders in the COMFORT-I immediate release formulation study and the extended release study. [Diagram 3] 1 is a graph comparing total symptom scores in the COMFORT-I immediate release formulation study and the extended release study. [Figure 4]1 is a graph comparing ruxolitinib steady-state plasma concentrations in MF patients receiving a 25 mg immediate release or a 25 mg extended release formulation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0010] sustained release dosage form The present invention provides, inter alia, an oral sustained release dosage form comprising, as an active ingredient, ruxolitinib or a pharma- ceutically acceptable salt thereof. The dosage form can contain ruxolitinib or a pharma- ceutically acceptable salt thereof in an amount of about 10 to about 60 mg, about 10 to about 40 mg, about 20 to about 40 mg, or about 20 to about 30 mg based on the free base. In some embodiments, the dosage form contains about 10 mg, about 12.5 mg, about 20 mg, about 25 mg, about 30 mg, about 37.5 mg, about 40 mg, about 50 mg, or about 60 mg based on the free base. In some embodiments, the dosage form contains about 25 mg of ruxolitinib based on the free base. The phrase "based on the free base" indicates that the amount of ruxolitinib or a salt thereof in the dosage form is measured based only on the molecular weight of ruxolitinib free base, even if the actual active ingredient is a salt of ruxolitinib that has a different molecular weight than the free base. For example, the conversion factor of ruxolitinib salt to the free base is 0.7575.
[0011] The structure, preparation and characterization of ruxolitinib and its pharmaceutically acceptable salts are described, for example, in U.S. Patent No. 7,598,257 and U.S. Patent Application Publication No. 2008 / 0312259, each of which is incorporated herein by reference in its entirety.In some embodiments, the active ingredient is a pharmaceutically acceptable salt of ruxolitinib, such as maleate, sulfate, or phosphate.In some embodiments, the active ingredient is ruxolitinib phosphate (i.e., phosphate of ruxolitinib).
[0012] The dosage forms of the present invention include sustained release formulations of ruxolitinib or a pharma- ceutically acceptable salt thereof. As used herein, "sustained release" is used as generally understood in the art and refers to a formulation that is designed to slowly release the active ingredient in a patient after oral administration and to maintain an essentially constant therapeutically effective plasma concentration of the active ingredient over a relatively extended period of time, such as from about 8 to about 24 hours or more.
[0013] The dosage forms of the present invention include a sustained release matrix forming agent. Exemplary sustained release matrix forming agents include cellulose ethers such as hydroxypropyl methylcellulose (HPMC, hypromellose), which is a high viscosity polymer. The sustained release dosage forms of the present invention can include, for example, about 10 to about 30% by weight, about 15 to about 25% by weight, or about 18 to about 24% by weight of hydroxypropyl methylcellulose(s). In some embodiments, the formulation has about 20% by weight of one or more hydroxypropyl methylcelluloses. In further embodiments, the formulation has about 22% by weight of one or more hydroxypropyl methylcelluloses. Exemplary hydroxypropyl methylcelluloses include Methocel K15M, Methocel K4M, and Methocel K100LV.
[0014] The sustained release dosage forms of the present invention may further include one or more fillers, glidants, disintegrants, binders, or lubricants as inactive ingredients. The fillers may be present in the formulation in an amount of 0 to about 85% by weight. In some embodiments, the formulation has about 50 to about 80% by weight, about 55 to about 75% by weight, or about 60 to about 70% by weight of the filler. Non-limiting examples of fillers include lactose monohydrate, microcrystalline cellulose, starch 1500, and anhydrous lactose, or combinations thereof. In some embodiments, the filler comprises microcrystalline cellulose, lactose monohydrate, or both.
[0015] Lubricants can be present in the dosage forms of the present invention in an amount of 0 to about 5% by weight. Non-limiting examples of lubricants include magnesium stearate, stearic acid (stearin), hydrogenated oils, polyethylene glycol, sodium stearyl fumarate, and glyceryl behenate. In some embodiments, the formulation includes magnesium stearate, stearic acid, or both.
[0016] The glidant may be present in the dosage form of the present invention in an amount of 0 to about 5% by weight. Non-limiting examples of glidants include talc, colloidal silicon dioxide, and cornstarch. In some embodiments, the glidant is colloidal silicon dioxide.
[0017] Disintegrants can be present in the dosage forms of the present invention in an amount of 0 to about 10% by weight. Non-limiting examples of disintegrants include croscarmellose sodium, crospovidone, starch, cellulose, and low-substituted hydroxypropyl cellulose. Croscarmellose sodium is the preferred disintegrant.
[0018] Film coating agents can be present in an amount of 0 to about 5% by weight. Non-limiting illustrative examples of film coating agents include hypromellose or polyvinyl alcohol-based coatings, with titanium dioxide, talc, and optionally colorants, in some commercially available complete coating systems.
[0019] In some embodiments, the dosage forms of the present invention comprise a sustained release formulation comprising about 12.2% ruxolitinib phosphate, about 20% hydroxypropyl methylcellulose, about 64.3% filler, about 2.5% lubricant, and about 1% glidant, all by weight.
[0020] In some embodiments, the dosage forms of the present invention comprise a sustained release formulation comprising about 12.2% ruxolitinib phosphate, about 22% hydroxypropyl methylcellulose, about 62.3% filler, about 2.5% lubricant, and about 1% glidant, all by weight.
[0021] In some embodiments, the dosage forms of the present invention comprise a sustained release formulation, as described below. [Table 1]
[0022] In some embodiments, the dosage forms of the present invention comprise a sustained release formulation, as described below. [Table 2]
[0023] In some embodiments, the dosage forms of the present invention comprise a sustained release formulation, as described below. [Table 3]
[0024] As used herein, the term "dosage form" is intended to refer to a physically discrete unit of the sustained release formulation of the present invention that is administered to a patient. Exemplary dosage forms include tablets, caplets, capsules, and the like, that contain any of the sustained release formulations described herein. The dosage form may further include a pharma- ceutically acceptable coating, pigment, or dye.
[0025] The dosage form of the present invention contains a sustained release formulation, which once administered, produces a relatively slow release of ruxolitinib, characterized by specific pharmacokinetic parameters different from those of fast release formulations.The sustained release dosage form of the present invention can minimize the potentially harmful spikes in drug plasma concentration associated with fast release formulations, and can help provide a continuous, constant, and therapeutically effective plasma concentration of drug.The dosage form of the present invention can be administered to human patients, for example, once a day, as needed for therapeutic effect against the disease being treated.
[0026] In some embodiments, the dosage form of the present invention is administered to a fasting patient.As used herein, "fasted" means, in relation to a human patient or subject, that the patient or subject has not consumed food or drink (except water) for at least 3 hours prior to administration.In some embodiments, the patient has fasted for at least 10 hours prior to administration.
[0027] In a further embodiment, the dosage form of the present invention is administered to a non-fasting human patient or subject. The bioavailability of ruxolitinib is high (e.g., about 70-80%) and no food effect has been observed in the immediate release dosage form. Therefore, the pharmacokinetics of ruxolitinib administered as a sustained release dosage form is not expected to be significantly different in fasting and non-fasting patients.
[0028] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean peak plasma concentration (C) of ruxolitinib of about 700 nM or less. max ) results.
[0029] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean peak plasma concentration (C) of ruxolitinib of about 600 nM or less. max ) results.
[0030] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean peak plasma concentration (C) of ruxolitinib of about 500 nM or less. max ) results.
[0031] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean peak plasma concentration (C) of ruxolitinib of about 400 nM or less. max ) results.
[0032] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean peak plasma concentration (C) of ruxolitinib of about 200 to about 700 nM. max ) results.
[0033] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean peak plasma concentration (C) of ruxolitinib of about 200 to about 600 nM. max ) results.
[0034] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean peak plasma concentration (C) of ruxolitinib of about 300 to about 500 nM. max ) results.
[0035] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean peak plasma concentration (C) of ruxolitinib of about 300 to about 400 nM. max ) results.
[0036] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean time to peak plasma concentration (T) of ruxolitinib of about 1.5 hours or greater. max ) results.
[0037] In some embodiments, administration of the sustained release dosage forms of the present invention to a human provides a mean time to peak plasma concentration (T) of ruxolitinib of about 1.5 hours to about 5 hours. max ) results.
[0038] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean time to peak plasma concentration (T) of ruxolitinib of about 2 hours to about 4 hours. max ) results.
[0039] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean 12-hour plasma concentration (C 12h ) versus mean peak plasma concentration (C max ) ratio.
[0040] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean 12-hour plasma concentration (C 12h ) versus mean peak plasma concentration (C max ) ratio.
[0041] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean 12-hour plasma concentration (C 12h ) versus mean peak plasma concentration (C max ) ratio.
[0042] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean 12-hour plasma concentration (C 12h ) versus mean peak plasma concentration (C max ) ratio.
[0043] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean 12-hour plasma concentration (C 12h ) versus mean peak plasma concentration (C max ) ratio.
[0044] In some embodiments, administration of the sustained release dosage forms of the present invention to a human results in a mean 12-hour plasma concentration (C 12h ) versus mean peak plasma concentration (C max ) ratio.
[0045] In some embodiments, administration of the sustained release dosage forms of the present invention to humans provides a mean half-life (t 1 / 2 ) results.
[0046] In some embodiments, administration of the sustained release dosage forms of the present invention to a human has a mean half-life (t 1 / 2 ) results.
[0047] In some embodiments, administration of a single dose of the sustained release dosage form of the invention to a human results in a mean bioavailability (AUC 0-∞ ) results.
[0048] In some embodiments, administration of a single dose of the sustained release dosage form of the invention to a human results in a mean bioavailability (AUC 0-∞ ) results.
[0049] In some embodiments, administration of a single dose of the sustained release dosage form of the invention to a human results in a mean bioavailability (AUC) of ruxolitinib of about 3000 to about 4000 nM*h. 0-∞ ) results.
[0050] In some embodiments, administration of a single dose of the sustained release dosage form of the invention to a human results in a mean bioavailability (AUC) of ruxolitinib of about 3100 to about 3800 nM*h. 0-∞ ) results.
[0051] In some embodiments, the sustained release dosage forms of the present invention have an average relative bioavailability in a patient based on AUC of about 65% to about 110% or about 75% to about 95% compared to an immediate release formulation containing the same amount of ruxolitinib or a pharma- ceutical acceptable salt thereof. AUC can be, for example, AUC 0-∞ (e.g., for a single dose) or AUC 0-t where t is a specified time.
[0052] As used herein, "average" when placed before a pharmacokinetic value (e.g., mean C max), unless otherwise specified, represent the arithmetic mean of pharmacokinetic values taken from a population of patients.
[0053] As used herein, "C max " means maximum observed plasma concentration.
[0054] As used herein, "C 12h " refers to the plasma concentration measured at 12 hours post-dose.
[0055] As used herein, "T max " refers to the time point at which maximum plasma concentration is observed.
[0056] As used herein, "T 1 / 2 " refers to the time point at which the plasma concentration is half of the maximum observed.
[0057] As used herein, "AUC" refers to the area under the plasma concentration-time curve, which is a measure of total bioavailability.
[0058] As used herein, "AUC 0-∞ " refers to the area under the plasma concentration-time curve extrapolated to infinity.
[0059] As used herein, "AUC 0-t " refers to the area under the plasma concentration-time curve from time 0 to the last time point with a quantifiable plasma concentration, usually about 12 to 36 hours.
[0060] As used herein, "AUC 0-τ " refers to the area under the plasma concentration-time curve from time 0 to the time of the next dose.
[0061] As used herein, "Cl / F" refers to oral clearance.
[0062] The sustained release dosage form of the present invention has certain advantages over the immediate release dosage form.The maintenance of a constant therapeutically effective plasma concentration of ruxolitinib provided by the sustained release dosage form of the present invention allows for reduced administration, such as administration only once a day, as opposed to twice or more for the immediate release form.Reduced administration can be helpful to patient compliance in the treatment plan of patients.
[0063] In some embodiments, administration of the sustained release dosage forms of the invention to a human results in a therapeutically effective plasma concentration of ruxolitinib for at least about 8 hours, at least about 10 hours, at least about 12 hours, at least about 18, or at least about 24 hours. In some embodiments, the sustained release dosage forms of the invention maintain a plasma concentration of between about 75 and about 500 nM for at least about 8 hours, at least about 12 hours, or at least about 18 hours. In some embodiments, the sustained release dosage forms of the invention maintain a plasma concentration of between about 100 and about 400 nM for at least about 6 hours or at least about 8 hours.
[0064] The additional advantage of sustained release dosage form (e.g., containing 25mg of ruxolitinib phosphate based on free base) includes reducing the undesirable side effects related to thrombocytopenia and anemia while maintaining the same therapeutic effect as fast release dosing schedule, e.g., 15mg or 20mg twice a day.It was not predictable that the sustained release formulation of ruxolitinib can both maintain therapeutic effect and significantly reduce the undesirable side effects related to thrombocytopenia or reduced hemoglobin level.The clinical data related to efficacy and side effects in myelofibrosis patients for both sustained release and fast release administration are compared in the examples.
[0065] In some embodiments, administration of the sustained release dosage forms of the present invention to a human once a day for at least 16 weeks provides a dose of about 100×10 9 / L or less, approximately 80×10 9 / L or less, approximately 60×10 9 / L or less, or about 40 x 109 resulting in a mean decrease in mean basal platelet count to below 1 / L.
[0066] In some embodiments, administration of the sustained release dosage forms of the present invention to a human once daily for at least 16 weeks results in a therapeutic effect of about 0×10 9 / L~Approx. 100×10 9 / L, approximately 30 x 10 9 / L~Approx. 80×10 9 / L, or approximately 50 × 10 9 / L~Approx. 70×10 9 / L resulting in a mean decrease in mean basal platelet count.
[0067] In some embodiments, administration of the sustained release dosage forms of the present invention to a human once daily for at least 16 weeks results in a mean decrease in mean baseline hemoglobin (Hgb) of about 15 g / L or less, about 10 g / L or less, about 8 g / L or less, or about 6 g / L or less.
[0068] In some embodiments, administration of the sustained release dosage forms of the invention to a human once daily for at least 16 weeks results in a mean reduction in mean baseline hemoglobin (Hgb) of about 0 to about 15 g / L, about 5 to about 15 g / L, about 2 to about 12 g / L, or about 5 to about 12 g / L.
[0069] In some embodiments, platelet counts and hemoglobin levels are measured in patients who have not received transfusions during the treatment period.
[0070] The mean baseline platelet count and mean baseline hemoglobin level are typically measured before initiation of treatment.
[0071] It is understood that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment (while it is contemplated that the embodiments may be combined as if written in multiple dependent form). Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.
[0072] method Another aspect of the present invention relates to a method of treating a JAK-associated disease or disorder in an individual (e.g., a patient) by administering to the individual in need thereof a sustained release dosage form of the present invention. A JAK-associated disease may include any disease, disorder, or condition that is directly or indirectly linked to the expression or activity of JAK, including overexpression and / or abnormal activity levels. A JAK-associated disease may also include any disease, disorder, or condition that can be prevented, ameliorated, or cured by modulating JAK activity.
[0073] Examples of JAK-associated diseases include diseases involving the immune system, including, for example, organ transplant rejection (eg, allograft rejection and graft-versus-host disease).
[0074] Further examples of JAK-associated diseases include autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, type 1 diabetes, lupus, psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, myasthenia gravis, immunoglobulin nephropathy, myocarditis, autoimmune thyroid disorders, chronic obstructive pulmonary disease (COPD), etc. In some embodiments, the autoimmune disease is an autoimmune bullous skin disorder such as pemphigus vulgaris (PV) or bullous pemphigoid (BP).
[0075] Further examples of JAK-associated diseases include allergic conditions such as asthma, food allergies, eszematous dermatitis, contact dermatitis, atopic dermatitis (atropic eczema), and rhinitis. Further examples of JAK-associated diseases include viral diseases such as Epstein-Barr virus (EBV), Hepatitis B, Hepatitis C, HIV, HTLV 1, Varicella Zoster Virus (VZV), and Human Papillomavirus (HPV).
[0076] Further examples of JAK-associated diseases include diseases associated with cartilage turnover, such as gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, painful dystrophy, Tietze's syndrome, costoathropathy, endemic osteoarthritis, Musereni disease, Handigodu disease, degeneration due to fibromyalgia, systemic lupus erythematosus, scleroderma, or ankylosing spondylitis.
[0077] Further examples of JAK-associated diseases include congenital cartilage malformations, including hereditary chrondrolysis, chrondrodysplasia, and pseudochrondrodysplasia (e.g., microtia, enotia, and metaphyseal chrondrodysplasia).
[0078] Further examples of JAK-related diseases or conditions include skin disorders such as psoriasis (e.g., psoriasis vulgaris), atopic dermatitis, skin rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis).For example, certain substances, including some drugs, when applied topically can cause skin sensitization.In some embodiments, simultaneous or sequential administration of at least one JAK inhibitor of the present invention with a drug that causes undesired sensitization can be useful for treating such undesired sensitization or dermatitis.In some embodiments, skin disorders are treated by topical administration of at least one JAK inhibitor of the present invention.
[0079] In further embodiments, the JAK-associated disease is cancer, including cancers characterized by solid tumors (e.g., prostate cancer, renal cancer, liver cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, head and neck cancer, thyroid cancer, glioblastoma, Kaposi's sarcoma, Castleman's disease, uterine leiomyosarcoma, melanoma, etc.), hematological cancers (e.g., leukemias such as lymphoma, acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), or multiple myeloma), and skin cancers such as cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell lymphoma. Exemplary CTCLs include Sézary syndrome and mycosis fungoides.
[0080] In some embodiments, JAK inhibitors in combination with other JAK inhibitors, as described herein or reported in U.S. Patent Application No. 11 / 637,545, the entirety of which is incorporated herein by reference, may be used to treat inflammation-associated cancer. In some embodiments, the cancer is associated with inflammatory bowel disease. In some embodiments, the inflammatory bowel disease is ulcerative colitis. In some embodiments, the inflammatory bowel disease is Crohn's disease. In some embodiments, the inflammation-associated cancer is colitis-associated cancer. In some embodiments, the inflammation-associated cancer is colon cancer or colorectal cancer. In some embodiments, the cancer is gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), adenocarcinoma, small intestine cancer, or rectal cancer.
[0081] JAK-associated diseases may further include those characterized by JAK2 mutants, such as those with at least one mutation in the pseudokinase domain (e.g., JAK2V617F); JAK2 mutants with at least one mutation outside the pseudokinase domain; JAK1 mutants; JAK3 mutants; erythropoietin receptor (EPOR) mutants; or deregulated expression of CRLF2.
[0082] JAK-associated diseases may further include myeloproliferative disorders (MPDs) such as polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), and systemic mast cell disease (SMCD). In some embodiments, the myeloproliferative disorder is myelofibrosis (e.g., primary myelofibrosis (PMF) or polycythemia vera / post-essential thrombocythemia myelofibrosis (PV / post-ET MF)). In some embodiments, the myeloproliferative disorder is post-essential thrombocythemia myelofibrosis (post-ET MF). In some embodiments, the myeloproliferative disorder is post-polycythemia vera myelofibrosis (post-PV MF).
[0083] The present invention further provides a method of treating psoriasis or other skin disorders by administration of a topical formulation containing a compound of the present invention.
[0084] In some embodiments, the sustained release formulations and dosage forms described herein can be used to treat pulmonary arterial hypertension.
[0085] In some embodiments, the sustained release formulations and dosage forms described herein can be used to treat mast cell activation syndrome.
[0086] The present invention further provides a method for treating the skin side effects of other preparations by administering the sustained release dosage form of the present invention.For example, many pharmaceutical products cause undesirable allergic reactions, which may appear as acne-like rashes or related dermatitis.Exemplary pharmaceutical products with such undesirable side effects include anticancer drugs such as gefitinib, cetuximab, erlotinib, etc.The dosage form of the present invention can be administered in combination (e.g., simultaneously or sequentially) with pharmaceutical products with undesirable skin side effects.
[0087] Further JAK-related diseases include inflammation and inflammatory diseases.Exemplary inflammatory diseases include sarcoidosis, inflammatory eye disease (for example, iritis, uveitis, scleritis, conjunctivitis or related diseases), inflammatory airway disease (for example, upper airway including nose and sinuses such as rhinitis or sinusitis, or lower airway including bronchitis, chronic obstructive pulmonary disease, etc.), inflammatory muscle disease such as myocarditis, and other inflammatory diseases.In some embodiments, the inflammatory eye disease is blepharitis.
[0088] The sustained release dosage forms described herein can further be used to treat ischemia-reperfusion injury or disease or condition associated with inflammatory ischemic events such as stroke or cardiac arrest. The sustained release dosage forms described herein can further be used to treat endotoxin-driven conditions (e.g., chronic endotoxin conditions that contribute to complications after bypass surgery or chronic heart failure). The sustained release dosage forms described herein can further be used to treat anorexia, cachexia, or fatigue, such as those caused by or associated with cancer. The sustained release dosage forms described herein can further be used to treat restenosis, sclerodermitis, or fibrosis. The sustained release dosage forms described herein can further be used to treat conditions associated with hypoxia or astrogliosis, such as, for example, diabetic retinopathy, cancer, or neurodegeneration. See, for example, Dudley, A. C. et al., Biochem. J. 2005, 390(Pt 2):427-36 and Sriram, K. et al., J. Biol. Chem. 2004, 279(19):19936-47. Epub 2004 Mar 2, both of which are incorporated by reference in their entireties. The sustained release dosage forms described herein can be used to treat Alzheimer's disease.
[0089] The sustained release dosage forms described herein may further be used to treat other inflammatory diseases, such as systemic inflammatory response syndrome (SIRS) and septic shock.
[0090] The sustained release dosage forms described herein may further be used to treat gout and increased prostate size due to, for example, benign prostatic hyperplasia or benign prostatic hyperplasia.
[0091] Further JAK-related diseases include bone resorption diseases such as osteoporosis, osteoarthritis, etc. Bone resorption can also be associated with other conditions such as hormonal imbalance and / or hormone therapy, autoimmune disease (e.g., bone sarcoidosis), or cancer (e.g., myeloma). The reduction in bone resorption by JAK inhibitors can be about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90%.
[0092] In some embodiments, the sustained release dosage forms described herein may further be used to treat dry eye disorder. As used herein, "dry eye disorder" is intended to encompass the conditions summarized in the recent official report of the Dry Eye Workshop (DEWS), which defines dry eye as "a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with the potential for ocular surface damage. It is accompanied by increased osmolality of the tear film and inflammation of the ocular surface." Lemp, "The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop", The Ocular Surface, 5(2), 75-92 April 2007 (incorporated herein by reference in its entirety). In some embodiments, the dry eye disorder is selected from aqueous tear-deficient dry eye (ADDE) or evaporative dry eye disorder, or a suitable combination thereof. In some embodiments, the dry eye disorder is Sjogren's syndrome dry eye (SSDE). In some embodiments, the dry eye disorder is non-Sjogren's syndrome dry eye (NSSDE).
[0093] In further aspects, the invention provides a method of treating conjunctivitis, uveitis (including chronic uveitis), chorioditis, retinitis, cyclitis, scleritis, episcleritis, or iritis; treating inflammation or pain associated with a corneal transplant, LASIK (laser in situ keratomileusis), laser refractive keratectomy, or LASEK (laser epithelial replacement keratomileusis); preventing vision loss associated with a corneal transplant, LASIK, laser refractive keratectomy, or LASEK; or preventing transplant rejection in a patient in need of a transplant, comprising administering to the patient a therapeutically effective amount of a compound of the invention, or a pharma- ceutical acceptable salt thereof.
[0094] In addition, the sustained release dosage forms of the present invention may be used to treat respiratory diseases or disorders associated with viral infections such as influenza and severe acute respiratory syndrome, optionally in combination with other JAK inhibitors such as those reported in U.S. patent application Ser. No. 11 / 637,545, the entirety of which is incorporated herein by reference.
[0095] As used herein, the terms "individual," "subject," or "patient" refer to a human being, who may or may not be fasting, when a dosage form of the present invention is administered.
[0096] As used herein, the term "pharmacologically acceptable" refers to compounds, materials, compositions, and / or dosage forms that are suitable for human contact without excessive toxicity, irritation, allergic response, and other problematic complications, within the scope of sound medical judgment, commensurate with a reasonable risk-benefit ratio.
[0097] As used herein, the term "treating" or "treatment" refers to one or more of: (1) preventing a disease, e.g., preventing a disease, condition, or disorder in an individual who may be susceptible to the disease, condition, or disorder but has not yet experienced or exhibited pathology or symptoms of the disease; (2) arresting a disease, e.g., arresting further development of the pathology and / or symptoms of the disease, condition, or disorder in an individual who is experiencing or exhibiting pathology or symptoms of the disease, condition, or disorder; and (3) ameliorating a disease, e.g., reducing the severity of the disease, in an individual who is experiencing or exhibiting pathology or symptoms of the disease, condition, or disorder (i.e., ameliorating the pathology and / or symptoms).
[0098] Combination therapy For example, one or more additional pharmaceutical agents, such as chemotherapeutic agents, anti-inflammatory agents, steroids, immunosuppressants, and Bcr-Abl, Flt-3, RAF, and FAK kinase inhibitors, such as those described in International Publication No. 2006 / 056399, which is incorporated herein by reference in its entirety, or other agents, may be used in combination with the sustained release dosage forms described herein for the treatment of JAK-associated diseases, disorders, or conditions. The one or more additional pharmaceutical agents may be administered to the patient simultaneously or sequentially.
[0099] Exemplary chemotherapeutic agents include proteosome inhibitors (eg, bortezomib), thalidomide, revlimid, and DNA damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.
[0100] Exemplary steroids include coriticosteroids such as dexamethasone or prednisone.
[0101] Exemplary Bcr-Abl inhibitors include the genera and species of compounds and pharma- ceutically acceptable salts thereof disclosed in U.S. Pat. No. 5,521,184, WO 04 / 005281, and U.S. patent application Ser. No. 60 / 578,491, all of which are incorporated herein by reference in their entireties.
[0102] Exemplary suitable Flt-3 inhibitors include the compounds and pharma- ceutically acceptable salts thereof disclosed in WO 03 / 037347, WO 03 / 099771, and WO 04 / 046120, all of which are incorporated herein by reference in their entireties.
[0103] Exemplary suitable RAF inhibitors include the compounds and pharma- ceutically acceptable salts thereof disclosed in WO 00 / 09495 and WO 05 / 028444, both of which are incorporated herein by reference in their entireties.
[0104] Exemplary suitable FAK inhibitors include the compounds and pharma- ceutically acceptable salts thereof disclosed in WO 04 / 080980, WO 04 / 056786, WO 03 / 024967, WO 01 / 064655, WO 00 / 053595, and WO 01 / 014402, all of which are incorporated herein by reference in their entireties.
[0105] In some embodiments, one or more of the compounds of the present invention may be used in combination with one or more other kinase inhibitors, including imatinib, particularly to treat patients who are resistant to imatinib or other kinase inhibitors.
[0106] In some embodiments, one or more JAK inhibitors of the present invention may be used in combination with chemotherapeutic agents in the treatment of cancers such as multiple myeloma, and may improve therapeutic response compared to the response to the chemotherapeutic agent alone, without exacerbating its toxic effects. Examples of additional pharmaceutical agents used in the treatment of multiple myeloma may include, but are not limited to, for example, melphalan, melphalan + prednisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib). Further additional agents used in the treatment of multiple myeloma include Bcr-Abl, Flt-3, RAF, and FAK kinase inhibitors. Additive or synergistic effects are desirable outcomes of combining the JAK inhibitors of the present invention with additional agents. Furthermore, resistance of multiple myeloma cells to agents such as dexamethasone may be reversible with treatment with the JAK inhibitors of the present invention. Agents may be combined with the compound in a single or sequential dosage form, or agents may be administered simultaneously or sequentially as separate dosage forms.
[0107] In some embodiments, a corticosteroid such as dexamethasone is administered to a patient in combination with at least one JAK inhibitor, where the dexamethasone is administered intermittently as opposed to continuously.
[0108] In some further embodiments, the combination with other therapeutic agents in sustained release dosage form may be administered to a patient before, during, and / or after bone marrow or stem cell transplantation.
[0109] In some embodiments, the additional therapeutic agent is fluocinolone acetonide (Retisert®) or rimexolone (AL-2178, Vexol, Alcon).
[0110] In some embodiments, the additional therapeutic agent is cyclosporine (Restasis®).
[0111] In some embodiments, the additional therapeutic agent is a corticosteroid. In some embodiments, the corticosteroid is triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.
[0112] In some embodiments, the additional therapeutic agent is selected from the group consisting of Dehydrex™ (Holles Labs), Civamide (Opko), sodium hyaluronate (Vismed, Lantibio / TRB Chemedia), cyclosporine (ST-603, Sirion Therapeutics), ARG101(T) (testosterone, Argentis), AGR1012(P) (Argentis), ecabet sodium (Senju-Ista), gefarnate (Santen), 15-(s)-hydroxyeicosatetraenoic acid (15(S)-HETE), cevilemine, doxycycline (ALTY-0501, Alacrity), minocycline, iDestrin™ (NP50301, Nascent Pharmaceuticals), cyclosporine A (Nova22007, Novagali), oxytetracycline (Duramycin, MOLI1901, Lantibio), CF101(2S,3S,4R,5R)-3,4-Dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyl-oxolane-2-carbamyl, Can-Fite Biopharma), voclosporin (LX212 or LX214, Lux Biosciences), ARG103 (Agentis), RX-10045 (synthetic resolvin analog, Resolvyx), DYN15 (Dyanmis Therapeutics), rivoglitazone (DE011, Daiichi Sanko), TB4 (RegeneRx), OPH-01 (Ophtalmis Monaco), PCS101 (Pericor Science), REV1-31 (Evolutec), Lacritin (Senju), rebamipide (Otsuka-Novartis), OT-551 (Othera), PAI-2 (University of Pennsylvania and Temple University) The therapeutic agent is selected from the group consisting of rifabutin, tacrolimus, pimecrolimus (AMS981, Novartis), loteprednol etabonate, rituximab, diquafosol tetrasodium (INS365, Inspire), KLS-0611 (Kissei Pharmaceuticals), dehydroepiandrosterone, anakinra, efalizumab, mycophenolate sodium, etanercept (Embrel®), hydroxychloroquine, NGX267 (TorreyPines Therapeutics), Actemra, gemcitabine, oxaliplatin, L-asparaginase, and thalidomide.
[0113] In some embodiments, the additional therapeutic agent is an angiogenesis inhibitor, a cholinergic agent, a TRP-1 receptor modulator, a calcium channel blocker, a mucin secretagogue, a MUC1 stimulator, a calcineurin inhibitor, a corticosteroid, a P2Y2 receptor agonist, a muscarinic receptor agonist, an mTOR inhibitor, another JAK inhibitor, a Bcr-Abl kinase inhibitor, an Flt-3 kinase inhibitor, a RAF kinase inhibitor, and a FAK kinase inhibitor, such as those described in International Publication No. 2006 / 056399, the entirety of which is incorporated herein by reference.In some embodiments, the additional therapeutic agent is a tetracycline derivative (e.g., minocycline or doxycline).In some embodiments, the additional therapeutic agent binds to FKBP12.
[0114] In some embodiments, the additional therapeutic agent is an alkylating or DNA crosslinking agent; antimetabolite / demethylating agent (e.g., 5-fluorouracil, capecitabine, or azacitidine); anti-hormonal therapy (e.g., hormone receptor antagonists, SERMs, or aromatase inhibitors); mitotic inhibitors (e.g., vincristine or paclitaxel); topoisomerase (I or II) inhibitors (e.g., mitoxantrone and irinotecan); apoptosis inhibitors (e.g., cytotoxic T cells, erythrocyte serine / erythrocyte endothelial cell line, or erythrocyte serine / erythrocyte endothelial cell line); inducers (e.g., ABT-737); nucleic acid therapy (e.g., antisense or RNAi); nuclear receptor ligands (e.g., agonists and / or antagonists: all-trans retinoic acid or bexarotene); epigenetic targeted agents such as histone deacetylase inhibitors (e.g., vorinostat), hypomethylating agents (e.g., decitabine); protein stability regulators such as Hsp90 inhibitors, ubiquitin and / or ubiquitin-like conjugating or unconjugating molecules; or EGFR inhibitors (erlotinib).
[0115] In some embodiments, the additional therapeutic agent(s) are analgesic eye drops (also known as "artificial tears"), including but not limited to compositions containing polyvinyl alcohol, hydroxypropylmethylcellulose, glycerin, polyethylene glycol (e.g., PEG400), or carboxymethylcellulose. Artificial tears can be useful in treating dry eye by compensating for reduced moisture and lubricating the tear film's ability. In some embodiments, the additional therapeutic agent is a mucolytic agent, such as N-acetyl-cysteine, which can interact with mucoproteins and thus reduce the viscosity of the tear film.
[0116] In some embodiments, the additional therapeutic agent includes antibiotics, antivirals, antifungals, anesthetics, anti-inflammatory agents including steroidal and non-steroidal anti-inflammatory drugs, and anti-allergy agents. Examples of suitable agents include aminoglycosides such as amikacin, gentamicin, tobramycin, streptomycin, netilmicin, and kanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin; naphthyridines; sulfonamides; polymyxins; chloramphenicol; neomycin; paramomycin; colistimethate; baclofenac ... These include citracin; vancomycin; tetracycline; rifampin and its derivatives ("rifampins"); cycloserine; beta-lactams; cephalosporins; amphotericin; fluconazole; flucytosine; natamycin; miconazole; ketoconazole; corticosteroids; diclofenac; flurbiprofen; ketorolac; suprofen; cromolyn; lodoxamide; levocabastine; naphazoline; antazoline; pheniramine; or azalide antibiotics.
[0117] The present invention will be described in more detail by specific examples.The following examples are provided for illustrative purposes and are not intended to limit the present invention in any way.Those skilled in the art will easily recognize various non-critical parameters that can be changed or modified to produce essentially the same results. Working Example EXAMPLES
[0118] Sustained-release and immediate-release formulations of ruxolitinib phosphate Formulation SR-2 A 25 mg sustained release formulation of ruxolitinib phosphate was prepared according to the following protocol. The formulation components are provided in Table 1a. Percentages are by weight. [Table 4]
[0119] protocol Step 1. Add microcrystalline cellulose, ruxolitinib phosphate, lactose monohydrate, and hypromellose to a suitable blender and mix. Step 2. The mixture from step 1 is transferred to a suitable granulator and mixed. Step 3. Add the purified water while mixing. Step 4. Sift the wet granules from step 3. Step 5. Transfer the granules from step 4 into a suitable dryer and dry until the LOD is 3% or less. Step 6. Sift the granules from step 5. Step 7. Mix colloidal silicon dioxide with the granules from Step 6 in a suitable blender. Step 8. Mix stearic acid and magnesium stearate with the mixture from step 7 and continue blending. Step 9. Compress the final blend of Step 8 on a suitable rotary tablet press.
[0120] Formulation SR-1 An alternative 25 mg sustained release formulation of ruxolitinib phosphate was prepared as described below. The formulation components are provided in Table 1b. Percentages are by weight. [Table 5]
[0121] protocol Step 1. Add microcrystalline cellulose, ruxolitinib phosphate, lactose monohydrate, and hypromellose to a suitable blender and mix. Step 2. The mixture from step 1 is transferred to a suitable granulator and mixed. Step 3. Add the purified water while mixing. Step 4. Sift the wet granules from step 3. Step 5. Transfer the granules from step 4 into a suitable dryer and dry until the LOD is 3% or less. Step 6. Sift the granules from step 5. Step 7. Mix colloidal silicon dioxide with the granules from Step 6 in a suitable blender. Step 8. Mix stearic acid and magnesium stearate with the mixture from step 7 and continue blending. Step 9. Compress the final blend of Step 8 on a suitable rotary tablet press.
[0122] Formulation C - Immediate release An immediate release dosage form of ruxolitinib phosphate is commercially available in doses of 5, 10, 15, 20, and 25 mg as the drug product Jakafi® (ruxolitinib phosphate (tablets)) (NDA No. N202192). The commercially available dosage form is identical to that used in the Phase III COMFORT-1 and COMFORT-II trials. EXAMPLES
[0123] Bioavailability test of sustained release formulations A comparative bioavailability study of sustained and fast release formulations of ruxolitinib phosphate was conducted in healthy adult volunteers.Fasted subjects received a single oral dose of fast release formulation (25 mg, see Example 1) or sustained release formulation (25 mg, see Example 1).Plasma concentrations of ruxolitinib were measured and are compared in Figure 1.Table 2a provides comparative pharmacokinetic (PK) data. [Table 6]
[0124] Bioavailability Testing Explained This study was conducted to evaluate the pharmacokinetic performance of two ruxolitinib phosphate extended release (SR) formulations compared to ruxolitinib phosphate immediate release (IR) tablets. The study was conducted as a three-period study, with all subjects fasting and taking IR tablets, SR-1 tablets, and SR-2 tablets. All treatments were administered as a single dose of one tablet. Nine healthy subjects enrolled in the study were randomized into two sequences to take IR tablets during the first period, and eight subjects who continued in the study were randomized into two sequences to take SR-1 and SR-2 tablets during the second and third periods.
[0125] The nine subjects enrolled in this study received a single dose of IR, SR-1, and SR-2 tablets according to a randomization schedule (see Table 2b). Doses were administered orally after an overnight fast of at least 10 hours, and a standardized meal was provided approximately 3 hours after dosing. There was a washout period of 7 days (minimum 5 days) between treatment periods.
[0126] Blood samples were collected for determination of plasma concentrations of ruxolitinib using lavender-top (K2EDTA) Vacutainer® tubes at 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, and 36 hours post-dose. No samples were collected for determination of urinary concentrations of ruxolitinib. [Table 7]
[0127] Plasma and urine samples were sent to Incyte Corporation for determination of ruxolitinib concentrations. Plasma samples were analyzed by a validated GLP, LC / MS / MS method with a linear range of 1-1000 nM.
[0128] All PK blood samples were collected within 5 minutes of their scheduled time, therefore, the scheduled times relative to the time of dose administration were used for all pharmacokinetic analyses.
[0129] Standard noncompartmental pharmacokinetic methods were used to analyze ruxolitinib plasma concentration data using Phoenix WinNonlin version 6.0 (Pharsight Corporation, Mountain View, CA). max and T max was taken directly from the observed plasma concentration data. lag ) was defined as the sampling time immediately preceding the time corresponding to the first measurable (nonzero) concentration. Log-linear regression of the concentration data during the terminal pharmacokinetic phase was used to calculate the terminal elimination rate constant (λ z ) and t 1 / 2 ln(2) / λ z The AUC was estimated using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. 0-t Estimate the total AUC 0-∞ AUC 0-t +C t / λ z Oral clearance (Cl / F) was calculated as Dose / AUC 0-∞ The terminal phase volume of distribution (V z / F) to Dose / [AUC 0-∞ *λ z ] was estimated.
[0130] Log-transformed pharmacokinetic parameters were compared between treatments using a two-way ANOVA with fixed factor for treatment and random factor for subject. C, calculated from adjusted means (least squares means) from the ANOVA max , AUC 0-t , and AUC 0-∞ The geometric mean relative bioavailability and 90% confidence intervals for were used to estimate the relative bioavailability of fasted administration of the SR formulation (test treatment) compared with fasted administration of the IR tablet (reference treatment). All statistical analyses were performed using SAS version 9.1 (SAS Institute, Inc., Cary, NC). EXAMPLES
[0131] Sustained release clinical trial A phase 2 clinical trial was conducted in patients with myelofibrosis (MF). A total of 41 subjects were enrolled, and spleen volume and total symptom scores were obtained at baseline. Tablets of the extended release formulation SR-2 (see Example 1) were administered to fasting patients. All patients were treated with 25 mg once daily for 8 weeks. After 8 weeks, depending on clinical response, the investigator was allowed to (a) maintain the same dose of SR-2, (b) increase the dose to 50 mg once daily, (c) increase the dose to alternating doses of 25 mg and 50 mg administered once daily, or (d) switch treatment to the immediate release formulation.
[0132] Data on spleen volume and total symptom score are provided in Figures 2 and 3, along with comparative data from the COMFORT-1 study, where patients received only the immediate release formulation. For details of the COMFORT-1 study, see Example A below. As can be seen from Figures 2 and 3, treatment with the 25 mg extended release formulation was nearly as effective as the immediate release formulation in the COMFORT-I study. The percentage of spleen volume responders for COMFORT-1 shown in Figure 2 was 39.4% and 43.9% at weeks 12 and 24, respectively. The percentage of spleen volume responders for the extended release study at week 16 was 28.9%. Similarly, the percentage of total symptom score responders for COMFORT-1 shown in Figure 3 was 46.3% and 45.9% at weeks 12 and 24, respectively. The percentage of total symptom score responders for the extended release study shown in Figure 3 was 36.8%.
[0133] Data regarding mean platelet counts and mean hemoglobin levels (Hgb) are shown below in Table 3 along with comparative data from the COMFORT-I study. As can be seen from the data, the mean change from baseline platelet count in SR patients was approximately half that observed in COMFORT-I. Similar results were seen for hemoglobin levels. Data are presented as mean ± SD. [Table 8] EXAMPLES
[0134] Comparison of steady-state plasma concentrations of ruxolitinib between SR and IR formulations in patients with MF The steady-state plasma concentrations of ruxolitinib in myelofibrosis (MF) patients receiving multiple doses of 25 mg between the sustained release (SR) and immediate release (IR) formulations are compared in Figure 4. Comparative pharmacokinetic parameters are provided below in Table 4a. [Table 9]
[0135] Description of an Open Label Study in Patients with MF overview This was an open-label study investigating the safety, tolerability, and efficacy of ruxolitinib administered orally in patients with primary myelofibrosis (PMF) and polycythemia vera / post-essential thrombocythemia myelofibrosis (PV / post-ET MF). The study consisted of three parts: Part 1 - dose escalation and expansion, administered twice daily, Part 2 - alternative dosing schedules (A, B, and C), and Part 3 - three separate patient groups (Groups I, II, and III). Eight dosing regimens were evaluated in the three parts. Part 1 evaluated two dose levels, 25 mg twice daily and 50 mg twice daily, part 2 tested five dosing regimens, 10 mg twice daily, 25 mg twice daily, 25 mg once daily, 50 mg once daily, and 100 mg once daily, and part 3 evaluated six dosing regimens, 10 mg twice daily, 15 mg twice daily, 25 mg twice daily, 50 mg once daily, 100 mg once daily, and 200 mg once daily. A total of 154 subjects were enrolled, with 32 subjects in part 1, 29 subjects in part 2, and 93 subjects in part 3. See Table 4b (qd=once daily, bid=twice daily).
[0136] In part 1, pharmacokinetic blood samples were collected using lavender-top (K3EDTA) Vacutainer® tubes pre-dose and 0.5, 1, 1.5, 2, 4, 6, and 9 hours post-dose on days 1 and 15 of cycle 1, and pre-dose on day 1 of cycles 2 and 3. In part 2, pharmacokinetic samples were collected pre-dose and 0.5, 1, 1.5, 2, 4, 6, and 9 hours post-dose on day 15 of cycle 1, and pre-dose on day 1 of cycles 2 and 3. In part 3, pharmacokinetic samples were collected pre-dose and 2 hours post-dose of the morning dose of ruxolitinib on day 15 of cycle 1 and day 1 of cycles 2 and 3.
[0137] Plasma concentration data from Cycle 1 for subjects in Parts 1 and 2 were used for the noncompartmental analysis, while all plasma concentration data were used for the population PK analysis.
[0138] Following oral administration of ruxolitinib phosphate tablets in the fasted state, either as a single dose or multiple doses, the drug was rapidly absorbed, typically reaching peak plasma concentrations within 0.3 to 2 hours after dosing in all subjects. Plasma concentrations subsequently declined in one or two steps.
[0139] average C max and AUC increased approximately linearly with dose from 10 mg to 100 mg. The pharmacokinetics of ruxolitinib in patients with MF were similar to those in healthy volunteers.
[0140] Detailed description of the clinical trial This multicenter, open-label, nonrandomized, dose-escalation clinical trial was conducted by MD Anderson Cancer Center (Houston, TX) and Mayo Clinic (Rochester, MN) according to Protocol INCB 18424-251 and involved 154 patients with PMF or post-PV / ET MF who received at least one single dose according to the study design in Table 4b. The study consisted of three parts: Part 1 - dose escalation and expansion cohorts, twice daily dosing, Part 2 - alternative dosing schedules (A, B, and C), and Part 3 - three separate patient groups (groups I, II, and III). Schedules A, B, and C in Part 2 were a once-daily (qd) dosing regimen, a lower dose of 10 mg twice daily, and an induction / maintenance regimen, respectively. Part 3 was studied in three separate patient groups to further evaluate the safety and efficacy of the selected starting dose levels and to explore dosing modifications on an individual patient basis, if necessary. Maintained doses and discontinuations for safety were defined in terms of platelet counts and absolute neutrophil counts (ANC), while conditions for dose escalation were provided based on inadequate efficacy defined by changes in spleen size.
[0141] Ruxolitinib phosphate tablets (5 and 25 mg) were administered as an oral dose with water in an outpatient setting. Doses ranged from 10 mg twice daily to 50 mg twice daily, and 25 mg once daily to 200 mg once daily. Individual patient participation was expected to be approximately 12 to 24 months. Patients may continue therapy indefinitely if they do not meet any of the discontinuation criteria, have no disease progression, and are deriving any clinical benefit.
[0142] In part 1, pharmacokinetic blood samples were collected using lavender-top (K3EDTA) Vacutainer® tubes pre-dose and 0.5, 1, 1.5, 2, 4, 6, and 9 hours post-dose on days 1 and 15 of cycle 1, and pre-dose on day 1 of cycles 2 and 3. In part 2, pharmacokinetic samples were collected pre-dose and 0.5, 1, 1.5, 2, 4, 6, and 9 hours post-dose on day 15 of cycle 1, and pre-dose on day 1 of cycles 2 and 3. In part 3, pharmacokinetic samples were collected pre-dose and 2 hours post-dose of the morning dose on day 15 of cycle 1 and day 1 of cycles 2 and 3. [Table 10]
[0143] Plasma samples were sent to Incyte Corporation and analyzed by a validated GLP, LC / MS / MS method with a linear range of 1-1000 nM and a limit of quantitation of 1 nM.
[0144] In general, actual times after dosing were used for the pharmacokinetic analysis. However, dosing information was not collected on cycle 1, day 15 for patients in part 2 and three additional patients in part 1. Nominal times were used for the pharmacokinetic analysis for these patients. Dosing information on cycle 1, day 15 for four additional patients was questionable. Therefore, nominal times were used for these patients as well. Steady-state AUC 0-τTo calculate RR, plasma concentrations 12 hours post-dose for twice daily or 24 hours post-dose for once daily on Cycle 1, Day 15 were imputed by the pre-dose sample on Cycle 1, Day 15.
[0145] Standard noncompartmental pharmacokinetic methods were used to analyze ruxolitinib plasma concentration data using WinNonlin version 6.0 (Pharsight Corporation, Mountain View, CA). max and T max was taken directly from the observed plasma concentration data. For single doses, log-linear regression of the concentration data during the terminal elimination phase was used to determine the terminal elimination rate constant (λ z ) and t 1 / 2 ln(2) / λ z The AUC was estimated using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. 0-t Estimate the total AUC 0-∞ AUC 0-t +C t / λ z Oral clearance (Cl / F) was calculated as Dose / AUC 0-∞ The terminal phase volume of distribution (V z / F) to Dose / [AUC 0-∞ *λ z ] was estimated.
[0146] For multiple dose data, log-linear regression of the concentration data during the terminal elimination phase was used to obtain λ z Estimate t 1 / 2 ln(2) / λ z The AUC over a dosing interval (AUC for dosing every 12 hours) was estimated using the linear trapezoidal rule for increasing concentrations and the logarithmic trapezoidal rule for decreasing concentrations. 0-12h or AUC for every 24 hours 0-24h Cl / F was estimated as Dose / AUC, and V z / F is Dose / [AUC*λ zIn addition, C min and AUC 0-t (area under the steady-state plasma concentration-time curve from time zero to the time the last sample was obtained) was calculated for multiple-dose data.
[0147] Descriptive statistics were used to summarize ruxolitinib PK parameters for each dose group, and one-way analysis of variance was used to compare log-transformed ruxolitinib PK parameters between dose groups. Power function regression models (e.g., C max = α Doseβ) to obtain C max and dose proportionality of AUC was assessed.
[0148] The pharmacokinetics of ruxolitinib in patients with MF were similar to those in healthy volunteers. EXAMPLES
[0149] Comparative effectiveness of sustained-release and immediate-release formulations Enlarged spleen is a common and prominent symptom of myelofibrosis. The reduction in spleen volume serves as a criterion for evaluating the effectiveness of a given treatment. Table 5a reports the mean reduction in spleen volume in MF patients who participated in the sustained release study (see Example 3) at week 16 of treatment, while Table 5b reports the mean reduction in spleen volume in MF patients who participated in the COMFORT-I study (fast release, see Comparative Example A) at week 24 of treatment. As can be seen from the data, both sustained release and fast release treatment regimens were effective in reducing spleen volume. [Table 11] [Table 12]
[0150] The effectiveness of a treatment plan in MF patients can also be evaluated by a total symptom score. In calculating the total symptom score, MF symptoms were assessed using a symptom diary (modified MFSAF v2.0 diary) in which subjects reported answers to questions about MF symptoms on a mobile device. Symptoms assessed included rapid / early satiety, abdominal discomfort, abdominal pain, lethargy, night sweats, itching, and bone / muscle pain.
[0151] Table 5c reports the Total Symptom Score results of the sustained release study (see Example 3), while Table 5d reports the Total Symptom Score results of the COMFORT-I study (immediate release, see Comparative Example A) at Week 24. As can be seen from the data, both the SR and IR dosing regimens were effective in treating MF in patients. [Table 13] [Table 14] EXAMPLES
[0152] Comparison of adverse events in patients participating in the extended-release and COMFORT-I (immediate-release) trials Data on adverse events related to anemia, thrombocytopenia, neutropenia, and all grade 3 or higher adverse events are compared in Table 6a for the sustained release and COMFORT-I (immediate release) studies (see Example 3 and Comparative Example A for a description of the study). Adverse events are graded according to the CTCAE criteria, which can be found online at ctep.cancer.gov / protocolDevelopment / electronic_applications / ctc.htm or evs.nci.nih.gov / ftp1 / CTCAE / CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Grade 3 adverse events generally correspond to severe or medically significant, but not immediately life-threatening, reactions for which hospitalization or prolonged hospitalization is indicated and the reaction is causing disability to the extent that it limits self-care. Higher grades are 4 (life-threatening, requiring emergency intervention) and 5 (death). For anemia, grade 3 corresponds to Hgb < 8.0 g / dL; < 4.9 mmol / L; < 80 g / L and a blood transfusion is indicated. For thrombocytopenia (low platelet count), grade 3 corresponds to < 50,000–25,000 / mm 3 ;<50.0~25.0x10 9 / L. Patient data were evaluated over a 16-week period. The mean duration of exposure to ruxolitinib in COMFORT-I was approximately 242 days. Typically, the majority of hematologic adverse events occur within the first few months of therapy, as observed in the COMFORT-I trial.
[0153] As can be seen from the data in Table 6a, adverse events considered grade 3 or higher, such as anemia, thrombocytopenia, neutropenia, and all-cause adverse events, occurred less frequently in the extended-release study compared with the COMFORT-I immediate-release study. [Table 15]
[0154] The occurrence of blood-related adverse events is further compared in Tables 6b and 6c, which report the number and percentage of patients in the study who showed certain reactions, including anemia and thrombocytopenia. The sustained release data for patients was evaluated over a 16-week period. The average duration of exposure to ruxolitinib in the COMFORT-I study was approximately 242 days. The majority of hematological adverse events occur within the first few months of therapy, as observed in the COMFORT-I study. As can be seen from the data in the table, the number and percentage of patients who showed blood-related adverse events were lower in the sustained release study. In addition, the severity of adverse events was less severe in the sustained release study. [Table 16] [Table 17]
[0155] Comparative example A COMFORT I Clinical Trial - Immediate Release Formulation A phase 3 clinical trial was completed demonstrating the efficacy of ruxolitinib in patients with myelofibrosis. In this double-blind study, patients with intermediate-2 or high-risk myelofibrosis were randomly assigned to receive oral, immediate-release (see Example 1) ruxolitinib twice daily (155 patients) or placebo (154 patients). The starting dose of ruxolitinib was determined by baseline platelet count: 15 mg twice daily for platelet counts between 100×109 and 200×109 per liter, and 20 mg twice daily for counts above 200×109 per liter. Dosage was adjusted for lack of efficacy or excessive toxicity. The primary endpoint was the proportion of patients with a ≥35% reduction in spleen volume at week 24, as assessed using magnetic resonance imaging. Secondary endpoints included durability of response, change in symptom burden (assessed by total symptom score), and overall survival.
[0156] The proportion of patients with a 35% or greater reduction in spleen volume at week 24 (the primary end point) was 41.9% in the ruxolitinib group compared with 0.7% in the placebo group. The proportion of patients with a 50% or greater reduction in total symptom score from baseline to week 24, a prespecified secondary end point, was significantly higher in the ruxolitinib group than in the placebo group (45.9% vs. 5.3%; odds ratio, 15.3; 95% confidence interval, 6.9 to 33.7; P<0.001).
[0157] The study showed that ruxolitinib was associated with a reduction in symptoms, prominent signs of splenomegaly and myelofibrosis, and appeared to be associated with improved overall survival. In addition, the most common toxic effects of anemia and thrombocytopenia were generally managed with dose modifications. Details regarding this study are provided in Verstovsek, S. et al., "A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis," N. Eng. J. Med., 2012, Mar 1:366(9):799-807, which is incorporated herein by reference in its entirety.
[0158] Comparative example B COMFORT II Clinical Trial - Immediate Release Formulation A phase 3 clinical trial has been completed demonstrating the superiority of ruxolitinib treatment in patients with myelofibrosis compared to best available therapy. Sequential ruxolitinib therapy compared to best available therapy was associated with significant and sustained reductions in splenomegaly and disease-related symptoms, improvements in role-playing and quality of life, and minimal toxic effects.
[0159] Myelofibrosis patients were randomly assigned in a 2:1 ratio to receive the best available therapy, which included ruxolitinib, or any commercially available agent (as monotherapy or in combination), or no therapy, and which could be changed during the treatment phase. The starting dose of ruxolitinib tablets was 15 mg twice daily of the immediate release formulation (see Example 1) if the baseline platelet count was ≤ 200 x 109 per liter, and 20 mg orally twice daily if the baseline platelet count was > 200 x 109 per liter.
[0160] The primary endpoint was a 35% or greater reduction in spleen volume from baseline at week 48. At week 48, the majority of patients in the ruxolitinib group had a reduction in spleen volume. Only patients in the ruxolitinib group met the primary endpoint criterion of at least a 35% reduction in spleen volume from baseline at week 48 (28%, vs. 0% in the best available therapy group; P<0.001). Patients in the ruxolitinib group compared with patients receiving best available therapy had improved quality of life and role-functioning. At week 48, patients receiving ruxolitinib had a significant reduction in symptoms associated with myelofibrosis, including loss of appetite, dyspnea, fatigue, insomnia, and pain, whereas patients receiving best available therapy experienced worsening symptoms.
[0161] Thrombocytopenia and anemia occurred more frequently in patients receiving ruxolitinib than in patients receiving best available therapy, but these events were generally manageable with dose modification, packed red blood cell transfusion, or both. Further details of the study are provided in Harrison, C. et al., "JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis," N. Eng. J. Med., 2012, Mar 1;366(9):787-98, which is incorporated herein by reference in its entirety.
[0162] In addition to those described herein, various modifications of the present invention will become apparent to those skilled in the art from the above description. Such modifications are also intended to fall within the scope of the appended claims. Each reference, including all patents, patent applications, and publications cited in this application, is hereby incorporated by reference in its entirety. The present invention includes the following aspects: [1] A sustained release dosage form comprising at least one active ingredient that is ruxolitinib or a pharma- ceutical acceptable salt thereof, wherein said ruxolitinib or a pharma-ceutical acceptable salt thereof is present in said dosage form in an amount of about 10 to about 60 mg on a free base basis. [2] The sustained release dosage form of [1], wherein the ruxolitinib or a pharma- ceutically acceptable salt thereof is present in the dosage form in an amount of about 25 mg based on the free base. [3] The sustained release dosage form of [1] or [2], wherein the active ingredient is ruxolitinib phosphate. [4] Administration of the dosage form to humans results in a mean peak plasma concentration (C max ) The sustained release dosage form according to any one of [1] to [3]. [5] Administration of the dosage form to a human results in a mean peak plasma concentration (C) of ruxolitinib of about 200 to about 700 nM. max ) The sustained release dosage form according to any one of [1] to [3]. [6] Administration of the dosage form to a human results in a mean peak plasma concentration (C) of ruxolitinib of about 300 to about 400 nM. max ) The sustained release dosage form according to any one of [1] to [3]. [7] Administration of the dosage form in a human subject has a mean time to peak plasma concentration (T max ) The sustained release dosage form according to any one of [1] to [6]. [8] Administration of the dosage form to a human has a mean time to peak plasma concentration (T) of ruxolitinib of about 1.5 hours to about 5 hours. max) The sustained release dosage form according to any one of [1] to [6]. [9] Administration of the dosage form to a human results in a mean 12-hour plasma concentration (C 12h ) versus mean peak plasma concentration (C max ) The sustained release dosage form according to any one of [1] to [8].
[10] Administration of the dosage form to a human results in a mean 12-hour plasma concentration (C 12h ) versus mean peak plasma concentration (C max ) The sustained release dosage form according to any one of [1] to [8].
[11] Administration of the dosage form to humans has a mean half-life (t 1 / 2 ) The sustained release dosage form according to any one of [1] to
[10] .
[12] Administration of the dosage form to humans has an average half-life (t 1 / 2 ) The sustained release dosage form according to any one of [1] to
[10] .
[13] Administration of a single dose of the dosage form to humans results in a mean bioavailability (AUC) of ruxolitinib of about 3000 to about 4000 nM*h. 0-∞ ) The sustained release dosage form according to any one of [1] to
[12] .
[14] A single dose of the dosage form administered to a human is about 3100 to about 3800 nM * The mean bioavailability (AUC 0-∞ ) The sustained release dosage form according to any one of [1] to
[12] .
[15] The sustained release dosage form according to any one of [1] to
[12] , comprising one or more cellulose ethers.
[16] The sustained release dosage form of
[15] , comprising hydroxypropyl methylcellulose.
[17] The sustained release dosage form of
[15] , comprising about 10% by weight to about 30% by weight of hydroxypropyl methylcellulose.
[18] The sustained release dosage form according to any one of [1] to
[17] , which is in the form of a tablet or capsule.
[19] A sustained release dosage form described in any one of [1] to
[18] , comprising 25 mg of ruxolitinib or a pharma- ceutically acceptable salt thereof, based on the free base, and wherein administration to a patient results in an average ruxolitinib plasma concentration of about 75 to about 500 nM for at least about 8 hours.
[20] The sustained release dosage form according to
[19] , comprising 12-13% by weight of ruxolitinib phosphate and 19-23% by weight of one or more hypromelloses, based on the free base.
[21] The sustained release dosage form of
[19] , comprising 12.2% by weight of ruxolitinib phosphate and 20% by weight or 22% by weight of one or more hypromelloses, based on the free base.
[22] A sustained release dosage form described in any one of
[19] to
[21] , wherein administration to a patient results in a ruxolitinib plasma concentration of about 75 to about 500 nM for at least about 8 hours.
[23] A sustained release dosage form described in any one of
[19] to 21], wherein administration to a patient results in a ruxolitinib plasma concentration of about 75 to about 500 nM for at least about 12 hours.
[24] Based on the free base, administration of the dosage form to a patient containing 25 mg of ruxolitinib phosphate for at least 16 weeks resulted in a patient receiving approximately 100×10 9 The sustained release dosage form according to any one of [1] to
[23] , which results in a mean reduction in mean basal platelet count of 0.1 to 0.2 mg / mL or less.
[25] Administration of the dosage form to a patient for at least 16 weeks results in a median mortality rate of approximately 80×10 9 3. The sustained release dosage form of claim 24, which results in a mean reduction in mean basal platelet count of 0.1 mg / mL or less.
[26] Administration of the dosage form to a patient for at least 16 weeks results in a median mortality rate of approximately 60×10 9 3. The sustained release dosage form of claim 24, which results in a mean reduction in mean basal platelet count of 0.1 mg / mL or less.
[27] Administration of the dosage form to a patient for at least 16 weeks results in a median mortality rate of approximately 40×10 93. The sustained release dosage form of claim 24, which results in a mean reduction in mean basal platelet count of 0.1 mg / mL or less.
[28] A sustained release dosage form according to any one of [1] to
[27] , comprising 25 mg of ruxolitinib salt on a free base basis, wherein administration of the dosage form to a patient for at least 16 weeks results in an average decrease in mean hemoglobin of about 15 g / L or less.
[29] The sustained release dosage form of
[28] , wherein administration of the dosage form to a patient for at least 16 weeks results in a mean decrease in mean hemoglobin of about 10 g / L or less.
[30] The sustained release dosage form of
[28] , wherein administration of the dosage form to a patient for at least 16 weeks results in a mean decrease in mean hemoglobin of about 8 g / L or less.
[31] The sustained release dosage form of
[28] , wherein administration of the dosage form to a patient for at least 16 weeks results in a mean decrease in mean hemoglobin of about 6 g / L or less.
[32] The sustained release dosage form according to any one of [1] to
[31] , comprising (1) ruxolitinib phosphate or a pharma- ceutically acceptable salt thereof, (2) microcrystalline cellulose, (3) hypromellose, (4) lactose monohydrate, (5) colloidal silicon dioxide, (6) magnesium stearate, and (7) stearic acid.
[33] A method of treating a disease associated with JAK activity in a patient in need thereof, comprising administering to the patient a dosage form according to any one of [1] to
[32] , wherein the disease is an autoimmune disease, a skin disorder, an allograft rejection, a graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, juvenile arthritis, type I diabetes, lupus, an inflammatory bowel disease, Crohn's disease, myasthenia gravis, immunoglobulin nephropathy, myocarditis, an autoimmune thyroid disorder, a viral disease, Epstein-Barr virus (EBV), hepatitis B, hepatitis C, HIV, or HTLV. 1. A method selected from varicella zoster virus (VZV), human papillomavirus (HPV), cancer, myeloproliferative disorders, inflammatory disorders, inflammatory eye disorders, iritis, uveitis, scleritis, conjunctivitis, inflammatory airway disorders, inflammatory upper respiratory tract disorders, inflammatory lower respiratory tract disorders, inflammatory myopathies, myocarditis, disorders associated with ischemia-reperfusion or ischemic events, anorexia or cachexia resulting from or associated with cancer, fatigue resulting from or associated with cancer, bone resorption disorders, or mast cell activation syndrome.
[34] The method according to
[33] , wherein the autoimmune disease is a blistering skin disorder.
[35] The method according to
[34] , wherein the bullous skin disorder is pemphigus vulgaris (PV) or bullous pemphigoid (BP).
[36] The method according to
[33] , wherein the skin disorder is atopic dermatitis, psoriasis, skin sensitization, skin irritation, skin rash, contact dermatitis, or allergic contact sensitization.
[37] The method according to
[36] , wherein the skin disorder is psoriasis.
[38] The method according to
[33] , wherein the myeloproliferative disorder (MPD) is polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia (CMML), hypereosinophilic syndrome (HES), or systemic mast cell disease (SMCD).
[39] The method according to
[38] , wherein the disease is primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF), polycythemia vera (PV), or essential thrombocythemia (ET).
[40] The method according to
[38] , wherein the disease is primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF).
[41] The method according to
[33] , wherein the cancer is a solid tumor, myeloma, prostate cancer, renal cancer, liver cancer, breast cancer, lung cancer, thyroid cancer, Kaposi's sarcoma, Castleman's disease, pancreatic cancer, blood cancer, lymphoma, leukemia, multiple myeloma, skin cancer, cutaneous T-cell lymphoma, or cutaneous B-cell lymphoma.
[42] The method according to
[33] , wherein the bone resorption disease is osteoporosis, osteoarthritis, bone resorption associated with hormonal imbalance, bone resorption associated with hormone therapy, bone resorption associated with autoimmune disease, or bone resorption associated with cancer.
[43] The method of
[33] , wherein the oral dosage form is administered once daily.
Claims
1. 1. An oral sustained release dosage form comprising ruxolitinib phosphate and a means for sustained release of said ruxolitinib phosphate, the ruxolitinib phosphate is present in the dosage form in an amount of 10 to 60 mg on a free base basis; The dosage form is suitable for oral administration, Administration of the dosage form to a human results in a ratio of mean peak plasma concentration (C max ) to mean 12-hour plasma concentration (C 12h ) of ruxolitinib of 10 or less; and Administration of said dosage form to humans results in a mean half-life (t 1 / 2 ) of 3.5 to 11 hours; Oral sustained release dosage forms.
2. An oral sustained release dosage form as described in claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 10 mg based on the free base.
3. An oral sustained release dosage form as described in claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 12.5 mg based on the free base.
4. An oral sustained release dosage form as described in claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 20 mg based on the free base.
5. 2. The oral sustained release dosage form of claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 25 mg on a free base basis.
6. An oral sustained release dosage form as described in claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 30 mg based on the free base.
7. An oral sustained release dosage form as described in claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 37.5 mg based on the free base.
8. An oral sustained release dosage form as described in claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 40 mg based on the free base.
9. An oral sustained release dosage form as described in claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 50 mg based on the free base.
10. An oral sustained release dosage form as described in claim 1, wherein the ruxolitinib phosphate is present in the dosage form in an amount of 60 mg based on the free base.
11. Administration of the dosage form to humans results in a mean 12-hour plasma concentration (C 12h ) versus mean peak plasma concentration (C max 11. The oral sustained release dosage form of claim 1, wherein the ratio of
12. Administration of the dosage form to humans resulted in a mean 12-hour plasma concentration (C 12h ) versus mean peak plasma concentration (C max 12. The oral sustained release dosage form of claim 1, wherein the ratio of
13. Administration of the dosage form to a human has a mean half-life (t 1/2 13. The oral sustained release dosage form of claim 1, wherein
14. An oral sustained release dosage form described in any one of claims 1 to 13, wherein the dosage form has an average relative bioavailability based on AUC of 65% to 110% in humans compared to an immediate release formulation containing the same amount of ruxolitinib phosphate.
15. 15. The oral sustained release dosage form of any one of claims 1 to 14, in the form of a tablet.
16. The oral sustained release dosage form of any one of claims 1 to 14, in the form of a capsule.
17. The oral sustained release dosage form of any one of claims 1-16, wherein administration of said dosage form to a human results in a mean time to peak plasma concentration (T max ) of ruxolitinib of 1.5 hours to 5 hours.
18. A pharmaceutical composition for treating a disease selected from myelofibrosis, polycythemia vera, and graft-versus-host disease in a patient in need thereof, comprising:
18. An oral sustained release dosage form comprising the oral sustained release dosage form according to any one of claims 1 to 17, The dosage form is administered to the patient once daily.
19. The pharmaceutical composition described in claim 18, wherein the disease is myelofibrosis.
20. The pharmaceutical composition of claim 19, wherein the myelofibrosis is primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), or post-essential thrombocythemia myelofibrosis (post-ET MF).
21. The pharmaceutical composition described in claim 18, wherein the disease is polycythemia vera.
22. The pharmaceutical composition described in claim 18, wherein the disease is graft-versus-host disease.
23. The pharmaceutical agent described in claim 18, wherein administration of the dosage form to a human patient results in reduced thrombocytopenia and anemia compared to an immediate release dosing regimen.
